Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Clinical trial NCT03836261 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03836261
- Sponsor
- Acerta Pharma BV
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-25
- Primary completion
- 2027-01-31
- Enrollment
- 984
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.